210 related articles for article (PubMed ID: 16925792)
1. Fracture risk in patients with monoclonal gammopathy of undetermined significance.
Gregersen H; Jensen P; Gislum M; Jørgensen B; Sørensen HT; Nørgaard M
Br J Haematol; 2006 Oct; 135(1):62-7. PubMed ID: 16925792
[TBL] [Abstract][Full Text] [Related]
2. Fracture risk in monoclonal gammopathy of undetermined significance.
Melton LJ; Rajkumar SV; Khosla S; Achenbach SJ; Oberg AL; Kyle RA
J Bone Miner Res; 2004 Jan; 19(1):25-30. PubMed ID: 14753733
[TBL] [Abstract][Full Text] [Related]
3. The impact of M-component type and immunoglobulin concentration on the risk of malignant transformation in patients with monoclonal gammopathy of undetermined significance.
Gregersen H; Mellemkjaer L; Ibsen JS; Dahlerup JF; Thomassen L; Sørensen HT
Haematologica; 2001 Nov; 86(11):1172-9. PubMed ID: 11694403
[TBL] [Abstract][Full Text] [Related]
4. Malignant transformation in IgM monoclonal gammopathy of undetermined significance.
Montoto S; Rozman M; Rosiñol L; Nadal E; Giné E; Aymerich M; Ferrer A; Esteve J; Bosch F; López-Guillermo A; Bladé J; Montserrat E
Semin Oncol; 2003 Apr; 30(2):178-81. PubMed ID: 12720132
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal gammopathy of undetermined significance and risk of venous thromboembolism.
Gregersen H; Nørgaard M; Severinsen MT; Engebjerg MC; Jensen P; Sørensen HT
Eur J Haematol; 2011 Feb; 86(2):129-34. PubMed ID: 20942842
[TBL] [Abstract][Full Text] [Related]
6. The relationship between monoclonal gammopathy of undetermined significance and venous thromboembolic disease.
Cohen AL; Sarid R
Thromb Res; 2010 Mar; 125(3):216-9. PubMed ID: 19193398
[TBL] [Abstract][Full Text] [Related]
7. The risk of bacteremia in patients with monoclonal gammopathy of undetermined significance.
Gregersen H; Madsen KM; Sørensen HT; Schønheyder HC; Ibsen JS; Dahlerup JF
Eur J Haematol; 1998 Aug; 61(2):140-4. PubMed ID: 9714528
[TBL] [Abstract][Full Text] [Related]
8. [Study of monoclonal gammopathy in Kagawa Prefectural Central Hospital].
Uchida M; Taida N; Kanao M; Kagamihara H; Kuwajima M
Rinsho Byori; 2004 Jul; 52(7):574-9. PubMed ID: 15344556
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of a population based cohort with monoclonal proteinaemia.
Schaar CG; le Cessie S; Snijder S; Franck PF; Wijermans PW; Ong C; Kluin-Nelemans H
Br J Haematol; 2009 Jan; 144(2):176-84. PubMed ID: 19036113
[TBL] [Abstract][Full Text] [Related]
10. Lower bone mineral density in geriatric patients with monoclonal gammopathy of undetermined significance.
Dizdar O; Erman M; Cankurtaran M; Halil M; Ulger Z; Yavuz BB; Ariogul S; Pinar A; Harputluoglu H; Kars A; Celik I
Ann Hematol; 2008 Jan; 87(1):57-60. PubMed ID: 17874101
[TBL] [Abstract][Full Text] [Related]
11. Risk of cholecystitis in patients with cancer: a population-based cohort study in Denmark.
Thomsen RW; Thomsen HF; Nørgaard M; Cetin K; McLaughlin JK; Tarone RE; Fryzek JP; Sørensen HT
Cancer; 2008 Dec; 113(12):3410-9. PubMed ID: 18951518
[TBL] [Abstract][Full Text] [Related]
12. Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance.
Rajkumar SV; Kyle RA; Therneau TM; Clark RJ; Bradwell AR; Melton LJ; Larson DR; Plevak MF; Katzmann JA
Br J Haematol; 2004 Nov; 127(3):308-10. PubMed ID: 15491291
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of monoclonal gammopathy of undetermined significance in an elderly urban Korean population.
Park HK; Lee KR; Kim YJ; Cho HI; Eun Kim J; Woong Kim K; Jung Kim Y; Lee KW; Hyun Kim J; Bang SM; Lee JS
Am J Hematol; 2011 Sep; 86(9):752-5. PubMed ID: 21786289
[TBL] [Abstract][Full Text] [Related]
14. [Monoclonal gammopathies of undetermined significance].
Krizalkovicová V; Maisnar V; Pour L; Radocha J; Hájek R
Klin Onkol; 2008; 21(4):160-4. PubMed ID: 19102222
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance.
Kyle RA; Therneau TM; Rajkumar SV; Offord JR; Larson DR; Plevak MF; Melton LJ
Semin Oncol; 2003 Apr; 30(2):169-71. PubMed ID: 12720130
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of monoclonal gammopathy of undetermined significance.
Kyle RA; Therneau TM; Rajkumar SV; Larson DR; Plevak MF; Offord JR; Dispenzieri A; Katzmann JA; Melton LJ
N Engl J Med; 2006 Mar; 354(13):1362-9. PubMed ID: 16571879
[TBL] [Abstract][Full Text] [Related]
17. Incidence and evolution of monoclonal gammopathy of undetermined significance (MGUS) in Greece.
Anagnostopoulos A; Evangelopoulou A; Sotou D; Gika D; Mitsibounas D; Dimopoulos MA
Ann Hematol; 2002 Jul; 81(7):357-61. PubMed ID: 12185503
[TBL] [Abstract][Full Text] [Related]
18. Malignant evolution of monoclonal gammopathy of undetermined significance: analysis of 633 consecutive cases with a long term follow-up.
Veneri D; Aqel H; Franchini M; Krampera M; Zanotti R; Pizzolo G
Haematologica; 2004 Jul; 89(7):876-8. PubMed ID: 15257948
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease.
Srkalovic G; Cameron MG; Rybicki L; Deitcher SR; Kattke-Marchant K; Hussein MA
Cancer; 2004 Aug; 101(3):558-66. PubMed ID: 15274069
[TBL] [Abstract][Full Text] [Related]
20. [Incidence, clinico-biological characteristics, and clinical course of 1,203 monoclonal gammopathies (1971-1992)].
Giraldo P; Rubio-Félix D; Cortés T; Delgado P; Franco E; Gimeno J; Tapia M; Giralt M
Sangre (Barc); 1994 Oct; 39(5):343-50. PubMed ID: 7754438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
